Cargando…
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was ex...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254966/ https://www.ncbi.nlm.nih.gov/pubmed/34217228 http://dx.doi.org/10.1186/s10020-021-00331-1 |
_version_ | 1783717811087998976 |
---|---|
author | Qvick, Alvida Stenmark, Bianca Carlsson, Jessica Isaksson, Johan Karlsson, Christina Helenius, Gisela |
author_facet | Qvick, Alvida Stenmark, Bianca Carlsson, Jessica Isaksson, Johan Karlsson, Christina Helenius, Gisela |
author_sort | Qvick, Alvida |
collection | PubMed |
description | BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics. RESULTS: There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological subgroups of lung cancer was found (p = 0.465). Furthermore, significantly more variants were detected in patients with stage IIIb–IV disease compared to patients with stage I–IIIa (median 7 vs 4, p = 0.017). Plasma cfDNA mutational load was significantly associated with overall survival (p = 0.010). The association persisted when adjusted for stage and ECOG performance status (HR: 3.64, 95% CI 1.37–9.67, p = 0.009). Agreement between tumor and plasma samples significantly differed with stage; patients with stage IIIb–IV disease showed agreement in 88.2% of the cases with clinically relevant variants, compared to zero cases in stage I–IIIa (p = 0.004). Furthermore, one variant in EGFR, two in KRAS, and one in BRAF were detected in plasma but not in tumor samples. CONCLUSION: This study concludes that in the vast majority of advanced NSCLC patients a reliable variant analysis can be performed using liquid biopsy from plasma. Furthermore, we found that the number of variants in plasma is associated with prognosis, possibly indicating a strategy for closer follow up on this crucial patient group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00331-1. |
format | Online Article Text |
id | pubmed-8254966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82549662021-07-06 Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer Qvick, Alvida Stenmark, Bianca Carlsson, Jessica Isaksson, Johan Karlsson, Christina Helenius, Gisela Mol Med Research Article BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics. RESULTS: There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological subgroups of lung cancer was found (p = 0.465). Furthermore, significantly more variants were detected in patients with stage IIIb–IV disease compared to patients with stage I–IIIa (median 7 vs 4, p = 0.017). Plasma cfDNA mutational load was significantly associated with overall survival (p = 0.010). The association persisted when adjusted for stage and ECOG performance status (HR: 3.64, 95% CI 1.37–9.67, p = 0.009). Agreement between tumor and plasma samples significantly differed with stage; patients with stage IIIb–IV disease showed agreement in 88.2% of the cases with clinically relevant variants, compared to zero cases in stage I–IIIa (p = 0.004). Furthermore, one variant in EGFR, two in KRAS, and one in BRAF were detected in plasma but not in tumor samples. CONCLUSION: This study concludes that in the vast majority of advanced NSCLC patients a reliable variant analysis can be performed using liquid biopsy from plasma. Furthermore, we found that the number of variants in plasma is associated with prognosis, possibly indicating a strategy for closer follow up on this crucial patient group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00331-1. BioMed Central 2021-07-03 /pmc/articles/PMC8254966/ /pubmed/34217228 http://dx.doi.org/10.1186/s10020-021-00331-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Qvick, Alvida Stenmark, Bianca Carlsson, Jessica Isaksson, Johan Karlsson, Christina Helenius, Gisela Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title | Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title_full | Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title_fullStr | Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title_full_unstemmed | Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title_short | Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
title_sort | liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254966/ https://www.ncbi.nlm.nih.gov/pubmed/34217228 http://dx.doi.org/10.1186/s10020-021-00331-1 |
work_keys_str_mv | AT qvickalvida liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer AT stenmarkbianca liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer AT carlssonjessica liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer AT isakssonjohan liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer AT karlssonchristina liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer AT heleniusgisela liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer |